Stevens-Johnson Syndrome: Clinical Trials

9 trials for Stevens-Johnson Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 withdrawn, 2 not yet recruiting, 1 completed, 1 recruiting. 9 Phase 1, 8 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 19Withdrawn 3, Not yet recruiting 2, Completed 1, Recruiting 1, Terminated 1, Unknown 1
Phase 28Withdrawn 3, Completed 1, Not yet recruiting 1, Recruiting 1, Terminated 1, Unknown 1

Follow Stevens-Johnson Syndrome: new trials by email Literature Review of Stevens-Johnson Syndrome trials Research Report on Stevens-Johnson Syndrome

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Subconjunctival Humira for Boston Keratoprosthesis
Adalimumab Injection - Penetrating Keratoplasty, Multiple Graft Failure
Phase 1Not yet recruitingMassachusetts Eye and Ear Infirmary82026-10-012026-08-31
New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.
DARATUMUMAB (DARZALEX®) - Toxic Epidermal Necrolysis, Immunotherapy
Phase 1 / Phase 2Not yet recruitingHospices Civils de Lyon92025-10-292025-08-07
LYell SYndrome MEsenchymal Stromal Cells Treatment
Adipose derived stromal cells intravenously injected - Epidermal Necrolysis, Lyell Syndrome
Phase 1 / Phase 2RecruitingAssistance Publique - Hôpitaux de Paris152024-04-152025-08-01
Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis.
Single Dose, Double Dose - Chronic Conjunctivitis, Stevens-Johnson Syndrome
Phase 1 / Phase 2UnknownInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz202022-11-112024-07-08
Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis
Clobetasol 0.05% ointment, Placebo - Toxic Epidermal Necrolysis
Phase 1 / Phase 2WithdrawnUniversity of California, Davis2016-11-012019-08-09
Topical Infliximab in Autoimmune Eyes With Keratoprosthesis
topical infliximab - Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis (Lyell) Syndrome
Phase 1 / Phase 2WithdrawnJames Chodosh, MD, MPH2014-11-012017-04-07
Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis
Riboflavin - Chemical Injuries, Unspecified Complication of Corneal Transplant
Phase 1 / Phase 2CompletedJoseph B. Ciolino, MD12012-03-012019-10-21
Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)
Infliximab - Stevens-Johnson Syndrome, Corneal Blindness
Phase 1 / Phase 2WithdrawnMassachusetts Eye and Ear Infirmary2010-12-012015-11-04
Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis
Palifermin - Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome
Phase 1 / Phase 2TerminatedBrett King12010-10-012016-11-30

Narrower conditions

Pemphigoid, Benign Mucous Membrane (3)  ·  Arthritis, Rheumatoid (1)  ·  Autoimmune Diseases (1)  ·  Lupus Erythematosus, Systemic (1)  ·  Pemphigoid, Bullous (1)  ·  Syndrome (1)

Broader conditions

Chemically-Induced Disorders (9)  ·  Dermatitis (9)  ·  Drug Eruptions (9)  ·  Drug Hypersensitivity (9)  ·  Drug-Related Side Effects and Adverse Reactions (9)  ·  Erythema (9)  ·  Erythema Multiforme (9)  ·  Hypersensitivity (9)  ·  Hypersensitivity, Delayed (9)  ·  Immune System Diseases (9)  ·  Mouth Diseases (9)  ·  Skin Diseases (9)  ·  Skin Diseases, Vesiculobullous (9)  ·  Skin and Connective Tissue Diseases (9)  ·  Stomatitis (9)

Interventions

Infliximab (2)  ·  Adalimumab (1)  ·  Clobetasol (1)  ·  Fibroblast Growth Factor 7 (1)  ·  Ointments (1)  ·  Riboflavin (1)  ·  Solutions (1)  ·  daratumumab (1)

Sponsors

Massachusetts Eye and Ear Infirmary (2)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Brett King (1)  ·  Hospices Civils de Lyon (1)  ·  Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (1)  ·  James Chodosh, MD, MPH (1)  ·  Joseph B. Ciolino, MD (1)  ·  University of California, Davis (1)

Countries

United States (6)  ·  France (2)  ·  Canada (1)  ·  Spain (1)

Top investigators

James Chodosh, MD, MPH (2)  ·  Claes H Dohlman, MD, PhD (1)  ·  Emanual Maverakis, MD (1)  ·  Joseph Ciolino, MD (1)  ·  Mona Harissi-Dagher, MD (1)  ·  Saskia Oro, PhD (1)  ·  Thomas Dohlman, MD (1)

Results publications

PMID 26297574, PMID 28476287